Checkpoint Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
CKPT Nasdaq 8731 http://www.checkpointtx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Checkpoint Therapeutics Inc

Checkpoint Therapeutics to Participate in the B. Riley Securities’ 3rd Annual Oncology Conference - Jan 17th, 2023 1:30 pm
Checkpoint Therapeutics Submits Biologics License Application to FDA for Cosibelimab as a Treatment for Patients with Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma - Jan 4th, 2023 1:00 pm
Individual investors in Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) are its biggest bettors, and their bets paid off as stock gained 36% last week - Jan 1st, 2023 2:36 pm
Checkpoint Therapeutics Announces $7.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - Dec 15th, 2022 1:00 pm
Checkpoint Therapeutics Announces Reverse Stock Split - Dec 5th, 2022 9:30 pm
Checkpoint Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights - Nov 8th, 2022 9:30 pm
Checkpoint Therapeutics to Participate in Two Upcoming Investor Conferences - Sep 22nd, 2022 12:30 pm
Checkpoint Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights - Aug 12th, 2022 12:00 pm
We're Keeping An Eye On Checkpoint Therapeutics' (NASDAQ:CKPT) Cash Burn Rate - Jun 30th, 2022 2:19 pm
Checkpoint' Cancer Therapy Shows Almost 55% Response Rate In Skin Cancer Patients - Jun 16th, 2022 1:29 pm
Checkpoint Therapeutics Announces Positive Interim Results from Registration-Enabling Trial of Cosibelimab in Locally Advanced Cutaneous Squamous Cell Carcinoma - Jun 16th, 2022 11:30 am
Checkpoint Therapeutics Announces Presentation of Pivotal Trial Results of Cosibelimab at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting - Jun 6th, 2022 8:30 pm
Checkpoint Therapeutics to Participate in the H.C. Wainwright Global Investment Conference - May 19th, 2022 12:30 pm
Checkpoint Therapeutics Receives Pediatric Investigational Plan Waivers for Cosibelimab from the European Medicines Agency and U.K. Medicines & Healthcare Products Regulatory Agency - May 13th, 2022 12:30 pm
Checkpoint Therapeutics Reports First Quarter 2022 Financial Results and Recent Corporate Highlights - May 12th, 2022 8:30 pm
Checkpoint Therapeutics Announces Data Presentation of Pivotal Trial Results of Cosibelimab to be Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting - Apr 28th, 2022 12:00 pm
Checkpoint Therapeutics to Present at the Virtual Fortress Biotech R&D Summit Hosted by B. Riley Securities - Apr 4th, 2022 12:15 pm
Fortress Biotech Announces Virtual Two-Day R&D Summit Hosted by B. Riley Securities on Tuesday, April 5 and Wednesday, April 6, 2022 - Apr 1st, 2022 12:30 pm
Here's What Checkpoint Therapeutics, Inc.'s (NASDAQ:CKPT) Shareholder Ownership Structure Looks Like - Mar 31st, 2022 11:10 pm
Checkpoint Therapeutics Reports Full-Year 2021 Financial Results and Recent Corporate Highlights - Mar 28th, 2022 11:30 am